Covalon Technologies (CVE:COV) Reaches New 1-Year High at $3.31

Shares of Covalon Technologies Ltd. (CVE:COV) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$3.31 and last traded at C$3.20, with a volume of 47076 shares. The stock had previously closed at C$3.17.

Covalon Technologies Price Performance

The company has a current ratio of 5.24, a quick ratio of 6.45 and a debt-to-equity ratio of 4.98. The business’s fifty day moving average is C$2.57 and its 200 day moving average is C$1.85. The company has a market cap of C$80.18 million, a P/E ratio of -81.25 and a beta of 0.64.

Covalon Technologies (CVE:COV) last issued its earnings results on Wednesday, August 21st. The company reported C$0.06 earnings per share (EPS) for the quarter. The firm had revenue of C$9.22 million for the quarter. Covalon Technologies had a negative return on equity of 3.85% and a negative net margin of 2.82%. As a group, sell-side analysts anticipate that Covalon Technologies Ltd. will post 0.3 EPS for the current year.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.